{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T13:46:35Z","timestamp":1764510395920},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2011,6,17]],"date-time":"2011-06-17T00:00:00Z","timestamp":1308268800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1007\/s00432-011-0993-1","type":"journal-article","created":{"date-parts":[[2011,6,17]],"date-time":"2011-06-17T19:36:08Z","timestamp":1308339368000},"page":"1219-1228","source":"Crossref","is-referenced-by-count":38,"title":["Combination of ciglitazone, a peroxisome proliferator-activated receptor gamma ligand, and cisplatin enhances the inhibition of growth of human ovarian cancers"],"prefix":"10.1007","volume":"137","author":[{"given":"Yoshihito","family":"Yokoyama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing","family":"Xin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuhiko","family":"Shigeto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Mizunuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,6,17]]},"reference":[{"key":"993_CR1","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/0022-1759(94)90396-4","volume":"170","author":"SA Ahmed","year":"1994","unstructured":"Ahmed SA, Gogal RM Jr, Walsh JE (1994) A new rapid and simple non-radioactive assay to monitor and determine the proliferation of lymphocytes: an alternative to [3H]thymidine incorporation assay. J Immunol Methods 170:211\u2013224","journal-title":"J Immunol Methods"},{"key":"993_CR2","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1084\/jem.20021408","volume":"197","author":"H Amano","year":"2003","unstructured":"Amano H, Hayashi I, Endo H, Kitasato H, Yamashina S, Maruyama T, Kobayashi M, Satoh K, Narita M, Sugimoto Y, Murata T, Yoshimura H, Narumiya S, Majima M (2003) Host prostaglandin E2-EP3 signaling regulates tumor-associated angiogenesis and tumor growth. J Exp Med 197:221\u2013232","journal-title":"J Exp Med"},{"key":"993_CR3","doi-asserted-by":"crossref","first-page":"7561","DOI":"10.1128\/MCB.00605-06","volume":"26","author":"JS Annicotte","year":"2006","unstructured":"Annicotte JS, Iankova I, Miard S (2006) Peroxisome proliferator-activated receptor gamma regulates E-cadherin expression and inhibits growth and invasion of prostate cancer. Mol Cell Biol 26:7561\u20137574","journal-title":"Mol Cell Biol"},{"key":"993_CR4","doi-asserted-by":"crossref","first-page":"4181","DOI":"10.1158\/0008-5472.CAN-04-3441","volume":"65","author":"I Avis","year":"2005","unstructured":"Avis I, Maerinez A, Tauler J, Zudaire E, Mayburd A, Abu-Ghazaleh R, Ondrey F, Mulshine JL (2005) Inhibitors of the arachidonic acid pathway and peroxisome proliferator-activated receptor ligands have superadditive effects on lung cancer growth inhibition. Cancer Res 65:4181\u20134190","journal-title":"Cancer Res"},{"key":"993_CR5","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1124\/mol.104.009449","volume":"68","author":"EB Berry","year":"2005","unstructured":"Berry EB, Keelan JA, Helliwell RJ, Gilmour RS, Mitchell MD (2005) Nanomolar and micromolar effects of 15-deoxy-delta 12, 14-prostaglandin J2 on amnion-derived WISH epithelial cells: differential roles of peroxisome proliferator-activated receptors gamma and delta and nuclear factor kappa B. Mol Pharmacol 68:169\u2013178","journal-title":"Mol Pharmacol"},{"key":"993_CR6","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMra041842","volume":"351","author":"SA Cannistra","year":"2004","unstructured":"Cannistra SA (2004) Cancer of the ovary. N Engl J Med 351:2519\u20132529","journal-title":"N Engl J Med"},{"key":"993_CR7","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0014-5793(03)00672-0","volume":"547","author":"MC Catley","year":"2003","unstructured":"Catley MC, Chivers JE, Cambridge LM, Holden N, Slater DM, Staples KJ, Bergmann MW, Loser P, Barnes PJ, Newton R (2003) IL-1\u03b2-dependent activation of NF-\u03baB mediates PGE2 release via the expression of cyclooxygenase-2 and microsomal prostaglandin E synthase. FEBS Lett 547:75\u201379","journal-title":"FEBS Lett"},{"key":"993_CR8","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1093\/annonc\/mdf207","volume":"13","author":"G Ferrandina","year":"2002","unstructured":"Ferrandina G, Lauriola L, Zannoni GF, Ferrandina G, Lauriola L, Zannoni GF, Fagotti A, Fanfani F, Legge F, Maggiano N, Gessi M, Mancuso S, Ranelletti FO, Scambia G (2002) Increased cyclooxygenase-2 (COX-2) expression is associated with chemotherapy resistance and outcome in ovarian cancer patients. Ann Oncol 13:1205\u20131211","journal-title":"Ann Oncol"},{"key":"993_CR9","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/CAD.0b013e3280101006","volume":"18","author":"SV Fulzele","year":"2007","unstructured":"Fulzele SV, Chatterjee A, Shaik MS, Jackson T, Ichite N, Singh M (2007) 15-Deoxy-Delta12, 14-prostaglandin J2 enhances docetaxel anti-tumor activity against A549 and H460 non-small-cell lung cancer cell lines and xenograft tumors. Anticancer Drugs 18:65\u201378","journal-title":"Anticancer Drugs"},{"key":"993_CR10","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1083\/jcb.119.3.493","volume":"119","author":"Y Gavrieli","year":"1992","unstructured":"Gavrieli Y, Sherman Y, Ben-Sasson SA (1992) Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 119:493\u2013501","journal-title":"J Cell Biol"},{"key":"993_CR11","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S1470-2045(04)01509-8","volume":"5","author":"C Grommes","year":"2004","unstructured":"Grommes C, Landreth GE, Heneka MT (2004) Antineoplastic effects of peroxisome proliferators-activated receptor gamma agonists. Lancet Oncol 5:419\u2013429","journal-title":"Lancet Oncol"},{"key":"993_CR12","doi-asserted-by":"crossref","first-page":"R365","DOI":"10.1152\/ajpregu.2001.281.1.R365","volume":"281","author":"JW Gu","year":"2001","unstructured":"Gu JW, Elam J, Sartin A, Li W, Roach R, Adair TH (2001) Moderate levels of ethanol induce expression of vascular endothelial growth factor and stimulate angiogenesis. Am J Physiol Regul Integr Comp Physiol 281:R365\u2013R367","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"993_CR13","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1006\/gyno.1994.1055","volume":"52","author":"S Hamada","year":"1994","unstructured":"Hamada S, Kamada M, Frumoto H, Hirano T, Aono T (1994) Expression of glutathione S-transferase \u03c0 in human ovarian cancer as an indicator of resistance to chemotherapy. Gynecol Oncol 52:313\u2013319","journal-title":"Gynecol Oncol"},{"key":"993_CR14","first-page":"5379","volume":"43","author":"TC Hamilton","year":"1983","unstructured":"Hamilton TC, Young RC, McKoy WM, Grotzinger KR, Green JA, Chu EW, Whang-Peng J, Rogan AM, Green WR, Ozols RF (1983) Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3)1 with androgen and estrogen receptors. Cancer Res 43:5379\u20135389","journal-title":"Cancer Res"},{"key":"993_CR15","first-page":"1288","volume":"8","author":"RC Haydon","year":"2002","unstructured":"Haydon RC, Zhou L, Feng T, Breyer B, Cheng H, Jiang W, Ishikawa A, Peabody T, Montag A, Simon MA, He TC (2002) Nuclear receptor agonists as potential differentiation therapy agents for Human osteosarcoma. Clin Cancer Res 8:1288\u20131294","journal-title":"Clin Cancer Res"},{"key":"993_CR16","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1159\/000299085","volume":"18","author":"PK Heinonen","year":"1984","unstructured":"Heinonen PK, Metsa-Ketela T (1984) Prostaglandin and thromboxane production in ovarian cancer tissue. Gynecol Obstet Invest 18:225\u2013229","journal-title":"Gynecol Obstet Invest"},{"key":"993_CR17","first-page":"1","volume":"9","author":"HP Koeffler","year":"2003","unstructured":"Koeffler HP (2003) Peroxisome proliferator-activated gamma and cancer. Clin Cancer Res 9:1\u20139","journal-title":"Clin Cancer Res"},{"key":"993_CR18","doi-asserted-by":"crossref","first-page":"357","DOI":"10.4161\/cbt.1.4.7","volume":"1","author":"L Kopelovich","year":"2002","unstructured":"Kopelovich L, Fay JR, Glazer RI, Crowell JA (2002) Peroxisome proliferator-activated receptor modulators as potential chemopreventive agents. Mol Cancer Ther 1:357\u2013363","journal-title":"Mol Cancer Ther"},{"key":"993_CR19","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0163-7827(03)00037-7","volume":"43","author":"M Murakami","year":"2004","unstructured":"Murakami M, Kudo I (2004) Recent advances in molecular biology and physiology of the prostaglandin E2-biosynthetic pathway. Prog Lipid Res 43:3\u201335","journal-title":"Prog Lipid Res"},{"key":"993_CR20","doi-asserted-by":"crossref","first-page":"32783","DOI":"10.1074\/jbc.M003505200","volume":"275","author":"M Murakami","year":"2000","unstructured":"Murakami M, Naraba H, Tanioka T, Semmyo N, Nakatani Y, Kojima F, Ikeda T, Fueki M, Ueno A, Oh S, Kudo I (2000) Regulation of prostaglandin E2 biosynthesis by inducible membrane associated prostaglandin E2 synthase that acts in concert with cyclooxygenase-2. J Biol Chem 275:32783\u201332792","journal-title":"J Biol Chem"},{"key":"993_CR21","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/1476-4598-5-62","volume":"5","author":"K Rask","year":"2006","unstructured":"Rask K, Zhu Y, Wang W, Hedin L, Sundfeldt K (2006) Ovarian epithelial cancer: a role for PGE2-synthesis and signalling in malignant transformation and progression. Mol Cancer 5:62","journal-title":"Mol Cancer"},{"key":"993_CR22","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/sj.bjc.6602009","volume":"91","author":"A Sakamoto","year":"2004","unstructured":"Sakamoto A, Yokoyama Y, Umemoto M, Futagami M, Sakamoto T, Bing X, Mizunuma H (2004) Clinical implication of expression of cyclooxygenase-2 and peroxisome proliferator activated-receptor \u03b3 in epithelial ovarian tumours. Br J Cancer 91:633\u2013638","journal-title":"Br J Cancer"},{"key":"993_CR23","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1038\/2030","volume":"4","author":"P Sarraf","year":"1998","unstructured":"Sarraf P, Mueller E, Jones D, King FJ, DeAngelo DJ, Partridge JB, Holden SA, Chen LB, Singer S, Fletcher C, Spiegelman BM (1998) Differentiation and reversal of malignant changes in colon cancer through PPARgamma. Nat Med 4:1046\u20131052","journal-title":"Nat Med"},{"key":"993_CR24","first-page":"99","volume":"22","author":"K Shigemasa","year":"2003","unstructured":"Shigemasa K, Tian X, Gu L, Shiroyama Y, Nagai N, Ohama K (2003) Expression of cyclooxygenase-2 and its relationship to p53 accumulation in ovarian adenocarcinomas. Int J Oncol 22:99\u2013105","journal-title":"Int J Oncol"},{"key":"993_CR25","doi-asserted-by":"crossref","first-page":"12440","DOI":"10.1074\/jbc.M007237200","volume":"276","author":"K Subbaramaiah","year":"2001","unstructured":"Subbaramaiah K, Lin DT, Hart JC, Dannenberg AJ (2001) Peroxisome proliferator-activated receptor \u03b3 ligands suppress the transcriptional activation of cyclooxygenase-2. J Biol Chem 276:12440\u201312448","journal-title":"J Biol Chem"},{"key":"993_CR26","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0092-8674(00)81433-6","volume":"93","author":"M Tsujii","year":"1998","unstructured":"Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN (1998) Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93:705\u2013716","journal-title":"Cell"},{"key":"993_CR27","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1054\/bjoc.2001.2034","volume":"85","author":"M Umemoto","year":"2001","unstructured":"Umemoto M, Yokoyama Y, Sato S, Tsuchida S, Al-Mulla F, Saito Y (2001) Carbonyl reductase as a significant predictor of survival and lymph node metastasis in epithelial ovarian cancer. Br J Cancer 85:1032\u20131036","journal-title":"Br J Cancer"},{"key":"993_CR28","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1136\/gut.2004.047100","volume":"55","author":"D Wang","year":"2006","unstructured":"Wang D, Dubois RN (2006) Prostaglandins and cancer. Gut 55:115\u2013122","journal-title":"Gut"},{"key":"993_CR29","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1002\/cncr.22854","volume":"110","author":"B Xin","year":"2007","unstructured":"Xin B, Yokoyama Y, Shigeto T, Futagami M, Mizunuma H (2007) Inhibitory effect of meloxicam, a selective cyclooxygenase-2 inhibitor, and ciglitazone, a peroxisome proliferator-activated receptor gamma ligand, on the growth of human ovarian cancer. Cancer 110:791\u2013800","journal-title":"Cancer"},{"key":"993_CR30","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/carcin\/22.9.1379","volume":"22","author":"WL Yang","year":"2001","unstructured":"Yang WL, Frucht H (2001) Activation of the PPAR pathway induces apoptosis and COX-2 inhibition in HT-29 human colon cancer cells. Carcinogenesis 22:1379\u20131383","journal-title":"Carcinogenesis"},{"key":"993_CR31","doi-asserted-by":"crossref","first-page":"3950","DOI":"10.1158\/0008-5472.CAN-04-3990","volume":"65","author":"Y Yin","year":"2005","unstructured":"Yin Y, Russell RG, Dettin LE, Bai R, Wei ZL, Kozikowski AP, Kopelovich L, Glazer RI (2005) Peroxisome proliferators-activated receptor delta and gamma agonists differentially alter tumor differentiation and progression during mammary carcinogenesis. Cancer Res 65:3950\u20133957","journal-title":"Cancer Res"},{"key":"993_CR32","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/0090-8258(83)90160-9","volume":"16","author":"O Ylikorkala","year":"1983","unstructured":"Ylikorkala O, Kauppila A, Viinikka L (1983) Prostacyclin and thromboxane in ovarian cancer: effect of cytostatics and prostaglandin synthesis inhibitors. Gynecol Oncol 16:340\u2013345","journal-title":"Gynecol Oncol"},{"key":"993_CR33","first-page":"361","volume":"20","author":"Y Yokoyama","year":"1999","unstructured":"Yokoyama Y, Sakamoto T, Sato S, Saito Y (1999) Evaluation of cytoreductive surgery with pelvic and paraaortic lymphadenectomy and intermittent cisplatin-based combination chemotherapy for improvement of long-term survival in ovarian cancer. Eur J Gynaecol Oncol 20:361\u2013366","journal-title":"Eur J Gynaecol Oncol"},{"key":"993_CR34","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1158\/1535-7163.MCT-06-0722","volume":"6","author":"Y Yokoyama","year":"2007","unstructured":"Yokoyama Y, Xin B, Shigeto T, Umemoto M, Kasai-Sakamoto A, Futagami M, Tsuchida S, Al-Mulla F, Mizunuma H (2007a) Clofibric acid, a peroxisome proliferator-activated receptor \u03b1 ligand, inhibits growth of human ovarian cancer. Mol Cancer Ther 6:1379\u20131386","journal-title":"Mol Cancer Ther"},{"key":"993_CR35","first-page":"1","volume":"1","author":"Y Yokoyama","year":"2007","unstructured":"Yokoyama Y, Xin B, Shigeto T, Futagami M, Mizunuma H (2007b) Clofibric acid, a peroxisome proliferator-activated receptor alpha ligand, enhances a suppressive effect of cis-diaminedichloroplatinum on proliferation of ovarian carcinoma cells. Clin Med Insights Oncol 1:1\u20136","journal-title":"Clin Med Insights Oncol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-011-0993-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00432-011-0993-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-011-0993-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,20]],"date-time":"2020-06-20T06:15:35Z","timestamp":1592633735000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00432-011-0993-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6,17]]},"references-count":35,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2011,8]]}},"alternative-id":["993"],"URL":"https:\/\/doi.org\/10.1007\/s00432-011-0993-1","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,6,17]]}}}